An Introduction to Glaucoma
Numerous updates in the glaucoma treatment landscape have had a big impact on patient outcomes. The introduction of minimally invasive glaucoma surgeries (MIGS) and the approval of new drugs with new mechanisms of action, for the first time in decades, have transformed the landscape. Ongoing research into new drug delivery systems is likely to provide more effective and convenient treatments in the future.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Thomas V Johnson, AGS 2021: Current Status and Future Challenges of Stem Cell-based Retinal Ganglion Cell Transplantation in Glaucoma Therapy
We were delighted to speak with Dr Thomas V Johnson (Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA) and find out his thoughts on the current status and future challenges of stem cell-based retinal ganglion cell transplantation in glaucoma therapy, and the challenges and opportunities of the online format of this year’s virtual meeting. […]
Thomas V Johnson, AGS 2021: Cell Intrinsic and Microenvironmental Modulators of Human Stem Cell Derived RGC Survival and Retinal Integration Following Transplantation
It was a pleasure to speak to Dr Thomas V Johnson (Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA) about his presentation at AGS 2021, investigating cell intrinsic and microenvironmental modulators of retinal ganglion cell survival and retinal integration following transplantation. Questions What were the aims and design of your study investigating cell intrinsic […]
Qi Cui, AGS 2021: Promising Novel Therapies in Glaucoma and Meeting Highlights
It was great to speak with Dr Qi Cui (Scheie Eye Institute, University of Pennsylvania, PA, USA) about her views on the most promising novel therapies targeting risk factors other than intraocular pressure in glaucoma, and her highlights from AGS21. Questions What are the most promising novel therapies targeting risk factors other than intraocular pressure […]
Qi Cui, AGS 2021: The GLP-1R Agonist NLY01 Reduces Neuroinflammation and Protects against RGC Loss in a Preclinical Glaucoma Model
We were delighted to catch up with Dr Qi Cui (Scheie Eye Institute, University of Pennsylvania, PA, USA), who told us about her research on the GLP-1R agonist NLY01 and the next steps for clinical development. Questions What is NLY01 and what is the rationale for its use in glaucoma therapy? (00:20) Could you give […]
David Huang, AGS 2021: Predictive Value of Baseline Visual Field, Disc, and Optical Coherence Tomography Diagnoses on Subsequent Glaucoma Progression
It was a pleasure to speak with Prof. David Huang (OHSU Casey Eye Institute, Portland, OR, USA) about his presentation at AGS 2021 on the predictive value of baseline visual field, disc and optical coherence tomography diagnoses on subsequent glaucoma progression. Questions Prior to your study, what was already known about the ability of baseline […]
Luis Abegão Pinto, EGS 2020 – Programme Highlights and Reflections on 2020 (Part 2)
We were delighted to speak with our esteemed Editorial Board member, Luis Abegão Pinto (Lisbon University, Lisbon, Portugal) about the impact of the COVID-19 pandemic on management of patients with glaucoma, the challenges of organising a virtual conference and the highlights of the EGS 2020 programme. Questions What do you consider to be the highlights […]
Luis Abegão Pinto, EGS 2020 – Programme Highlights and Reflections on 2020 (Part 1)
We were delighted to speak with our esteemed Editorial Board member, Luis Abegão Pinto (Lisbon University, Lisbon, Portugal) about the impact of the COVID-19 pandemic on management of patients with glaucoma, the challenges of organising a virtual conference and the highlights of the EGS 2020 programme. Questions How has the COVID-19 pandemic impacted on the […]
The Effect of Inhaled Cannabis on Intraocular Pressure in Healthy Adult Subjects
US Ophthalmic Review. 2020;13(2):Epub ahead of journal publication
**This manuscript has been accepted for publication but not yet copyedited or typeset, and may be subject to minor changes during the production process.**
Once-daily Preservative-free Topical Anti-glaucomatous Monotherapy – A Better Approach?
European Ophthalmic Review. 2020;14(1):21–5 DOI: https://doi.org/10.17925/EOR.2020.14.1.21
Glaucoma causes an optic neuropathy and is one of the leading causes of blindness globally.1 Pathologically, patients with glaucoma typically develop irreversible characteristic field defects due to loss of retinal ganglion cells and subsequent characteristic optic nerve-head damage. The main risk factor for development of glaucoma is intraocular pressure (IOP), reduction of which is targeted by […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!